Allogene Therapeutics (ALLO) Leases: 2019-2025
Historic Leases for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $40.9 million.
- Allogene Therapeutics' Leases rose 224.88% to $40.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.9 million, marking a year-over-year increase of 224.88%. This contributed to the annual value of $45.2 million for FY2024, which is 29.04% down from last year.
- Allogene Therapeutics' Leases amounted to $40.9 million in Q3 2025, which was down 2.46% from $42.0 million recorded in Q2 2025.
- Allogene Therapeutics' 5-year Leases high stood at $86.8 million for Q2 2022, and its period low was $7.5 million during Q2 2024.
- Its 3-year average for Leases is $51.0 million, with a median of $45.2 million in 2024.
- In the last 5 years, Allogene Therapeutics' Leases spiked by 40,089.00% in 2021 and then crashed by 90.66% in 2024.
- Allogene Therapeutics' Leases (Quarterly) stood at $58.0 million in 2021, then skyrocketed by 44.05% to $83.6 million in 2022, then dropped by 23.79% to $63.7 million in 2023, then dropped by 29.04% to $45.2 million in 2024, then surged by 224.88% to $40.9 million in 2025.
- Its Leases was $40.9 million in Q3 2025, compared to $42.0 million in Q2 2025 and $44.1 million in Q1 2025.